Regeneron counsel Larosa exercises options for 12,283 shares

Separate from the option exercise, 8,686 shares were delivered or withheld for payment of exercise price or tax liability.

Available on EDGAR 11/04/2026 - 04:05 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:04 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. executive vice president and general counsel Joseph J. Larosa exercised options for 12,283 common shares on November 2, 2026, at an exercise price of $381.92 per share. On the same date, 8,686 shares were delivered or withheld for payment of exercise price or tax liability. Larosa also reported sales of 3,939 shares at a volume-weighted average price of $965.41 and 527 shares at $966.11. No Rule 10b5-1 plan is reported. His indirect holdings included 5,407 shares through a 2025 GRAT and 413 shares through a 401(k) Plan.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider LAROSA JOSEPH J

Role EVP General Counsel and Secret

Sold 4,466 shs ($4.31M)

Approx. gross sale proceeds $4.31M

Approx. exercise cost $4.69M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy) F3	12,283	$0.00	$0.00
Exercise	Common Stock	12,283	$381.92	$4.69M
Exercise Price or Tax Liability	Common Stock	8,686	$950.50	$8.26M
Sale	Common Stock F1	3,939	$965.41	$3.80M
Sale	Common Stock F2	527	$966.11	$509K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 38,906 shares (Direct); Common Stock — 5,407 shares (Indirect, By 2025 GRAT); Common Stock — 413 shares (Indirect, By 401(k) Plan)

Footnotes (3)

1. F1. Represents volume-weighted average price of sales of 3,939 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
2. F2. Represents volume-weighted average price of sales of 527 shares of Company stock on November 2, 2026 at prices ranging from $966.00 to $966.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
3. F3. The stock option award vested in four equal annual installments, commencing one year after the date of grant.

Key Figures

Shares acquired through option exercise: 12,283 shares Option exercise price: $381.92 per share Shares delivered or withheld: 8,686 shares +4 more

7 metrics

Shares acquired through option exercise 12,283 shares November 2, 2026

Option exercise price $381.92 per share November 2, 2026

Shares delivered or withheld 8,686 shares For payment of exercise price or tax liability

First sale 3,939 shares at a volume-weighted average price of $965.41 per share November 2, 2026

Second sale 527 shares at a volume-weighted average price of $966.11 per share November 2, 2026

Indirect holding through 2025 GRAT 5,407 shares Reported after the transactions

Indirect holding through 401(k) Plan 413 shares Reported after the transactions

Key Terms

Non-Qualified Stock Option, volume-weighted average price, GRAT, 401(k) Plan

4 terms

Non-Qualified Stock Option technical

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

volume-weighted average price financial

"volume-weighted average price of sales of 3,939 shares"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

GRAT financial

"By 2025 GRAT"

401(k) Plan financial

"By 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did Joseph J. Larosa sell, and at what prices?

Joseph J. Larosa reported sales on November 2, 2026, of 3,939 shares at a volume-weighted average price of $965.41 and 527 shares at $966.11. The corresponding sale-price ranges were $965.00 to $965.99 and $966.00 to $966.32. No Rule 10b5-1 plan is reported.

How many REGN shares did Larosa acquire through option exercise?

Larosa exercised options for 12,283 shares of common stock at an exercise price of $381.92 per share on November 2, 2026. The option award vested in four equal annual installments, commencing one year after the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAROSA JOSEPH J

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP General Counsel and Secret

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		12,283	A	$381.92	52,058	D
Common Stock	11/02/2026		F		8,686	D	$950.5	43,372	D
Common Stock	11/02/2026		S		3,939	D	$965.41(1)	39,433	D
Common Stock	11/02/2026		S		527	D	$966.11(2)	38,906	D
Common Stock								5,407	I	By 2025 GRAT
Common Stock								413	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$381.92	11/02/2026		M			12,283	(3)	12/16/2026	Common Stock	12,283	$0.0	0	D

Explanation of Responses:

1. Represents volume-weighted average price of sales of 3,939 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

2. Represents volume-weighted average price of sales of 527 shares of Company stock on November 2, 2026 at prices ranging from $966.00 to $966.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

3. The stock option award vested in four equal annual installments, commencing one year after the date of grant.

	/s/ Joseph LaRosa	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)